Rationale: Since their approval, there has been no real-world or randomized trial evidence
evaluating the effect of the antifibrotic medications pirfenidone and nintedanib on clinically …

There is no debate that idiopathic pulmonary fibrosis (IPF) is a devastating disease that has
a significant impact on patient morbidity and mortality. Patients with IPF experience …

Background Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple
comorbidities, which may influence survival but go under-recognised in clinical practice. We …

BACKGROUND: Additional real-world studies are needed to more fully elucidate the
effectiveness of antifibrotic treatment in slowing the progression of idiopathic pulmonary …

Rationale: Two antifibrotic medications, nintedanib and pirfenidone, have been approved for
the treatment of idiopathic pulmonary fibrosis (IPF) in the United States. Few data have been …

Background Idiopathic pulmonary fibrosis (IPF) is a serious interstitial lung disease (ILD)
with a median survival of 3-5 years. The aim of the present study was to evaluate disease …

Background: Antifibrotics are recommended for the treatment of individuals with idiopathic
pulmonary fibrosis (IPF), but treatment use remains at∼ 60%. Objective: To investigate the …

Throughout nearly two decades of clinical trial experience in idiopathic pulmonary fibrosis
(IPF), there has been ongoing debate over the optimal endpoint (s) on which to design trials …

BACKGROUND To ascertain whether findings from hospital based clinical series can be
extended to patients with idiopathic pulmonary fibrosis (IPF) in the general population, the …

Idiopathic pulmonary fibrosis (IPF) is characterised by unpredictable disease course and
poor survival. After the introduction of novel antifibrotic drugs, the prognosis of patients with …